JIANGSU TASLY DIYI PHARMACEUTICAL CO LTD

Overview

JIANGSU TASLY DIYI PHARMACEUTICAL CO LTD is an active pharmaceutical ingredient (API) supplier with 18 active FDA Type II Drug Master Files, covering (S)-2-AMINOBUTYRAMIDE HYDROCHLORIDE; 7 AMINO DESACETOXY CEPHALOSPORANIC ACID (7 ADCA); ACETOIODIDE (NON-STERILE, ACTIVE PHARMACEUTICAL INGREDIENT INTERMEDIATE); AMBRISENTAN; AZITHROMYCIN DIHYDRATE; BUSPIRONE HYDROCHLORIDE USP.

API / Drug Master Files

JIANGSU TASLY DIYI PHARMACEUTICAL CO LTD holds 18 active (20 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• LITHIUM CARBONATE USPActive2025-12-03
• IODIXANOL, USP, NON-STERILE, BULK DRUG SUBSTANCEActive2025-10-31
• RELUGOLIXActive2025-09-17
• IOHEXOL, USP, NON-STERILE, BULK DRUG SUBSTANCEActive2025-08-19
• BUSPIRONE HYDROCHLORIDE USPActive2024-12-31
• SITAGLIPTIN BASEActive2024-04-10
• PHENTOLAMINE MESYLATEActive2024-03-05
• SACUBITRIL VALSARTAN SODIUMActive2024-02-25
• ACETOIODIDE (NON-STERILE, ACTIVE PHARMACEUTICAL INGREDIENT INTERMEDIATE)Active2023-11-01
• PIMAVANSERIN TARTRATEActive2022-12-16
• HYDROCORTISONE ACETATEActive2021-08-06
• HYDROCORTISONEActive2021-08-05
• (S)-2-AMINOBUTYRAMIDE HYDROCHLORIDEActive2017-08-11
• 7 AMINO DESACETOXY CEPHALOSPORANIC ACID (7 ADCA)Active2017-06-20
• AZITHROMYCIN DIHYDRATEActive2016-12-29

Showing 15 of 20 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to JIANGSU TASLY DIYI PHARMACEUTICAL CO LTD in our records. PharmaTek screens the full directory against live FDA enforcement data.